Ipragliflozin + Insulin

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes Mellitus

Conditions

Type 2 Diabetes Mellitus

Trial Timeline

Jul 29, 2016 โ†’ Nov 9, 2017

About Ipragliflozin + Insulin

Ipragliflozin + Insulin is a approved stage product being developed by Astellas Pharma for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT02847091. Target conditions include Type 2 Diabetes Mellitus.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02847091ApprovedCompleted